Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
Presage’s device would allow oncologists to test potentially harmful compounds in tiny amounts before giving patients a full dose.
A compound derived from a toxin from scorpion venom could help neurosurgeons differentiate between healthy and cancerous brain tissue.
A hedge fund manager aims to solve the funding problems facing early-stage biomedical research.
IBM’s Blue Gene supercomputer uncovers a novel drug interaction site.
A biotech company called Cerulean says its nanoparticle-delivered cancer drugs are better at attacking tumors.
They could be the cause of cancer relapse—but may also offer new approaches to treatment.
One startup, H3 Biomedicines, uses genome data to design drugs aimed at small groups of patients.